Ryo Mizojiri

Ryo Mizojiri

Auto-generated profile, based on publicly available information

Ryo Mizojiri

Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 September 2019 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
JFJun Fujimoto
Jun Fujimoto
OKOsamu Kurasawa
Osamu Kurasawa
TTTerufumi Takagi
Terufumi Takagi
XLXin Liu
Xin Liu
HBHiroshi Banno
Hiroshi Banno
RMRyo Mizojiri
Ryo Mizojiri

5 January 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RMRyo Mizojiri
Ryo Mizojiri
MAMoriteru Asano
Moriteru Asano
DTDaisuke Tomita
Daisuke Tomita
HBHiroshi Banno
Hiroshi Banno
NNNoriyuki Nii
Noriyuki Nii
HMHironobu Maezaki
Hironobu Maezaki

14 September 2017 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
RMRyo Mizojiri
Ryo Mizojiri
DNDaisuke Nakata
Daisuke Nakata
YSYoshihiko Satoh
Yoshihiko Satoh
DMDaisuke Morishita
Daisuke Morishita
SSSachio Shibata
Sachio Shibata
YIYasuhiro Imaeda
Yasuhiro Imaeda
Starting from our previous eIF4A3-selective inhibitor 1a, a novel series of (piperazine-1-carbonyl)pyridin-2(1H)-one derivatives was designed, synthesized, and evaluated for identification of orally bioavailable probe molecules. Compounds 1o and 1q showed improved physicochemical and ADMET profiles, while maintaining potent and subtype-selective eIF4A3 inhibitory potency. In accord with their promising PK profiles and results from initial in vivo PD studies, compounds 1o and 1q showed antitumor efficacy with T/C values of 54% and 29%, respectively, without severe body weight loss. Thus, our novel series of compounds represents promising probe molecules for the in vivo pharmacological study of selective eIF4A3 inhibition.

1 December 2019 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
RMRyo Mizojiri
Ryo Mizojiri
MAMoriteru Asano
Moriteru Asano
MSMasako Sasaki
Masako Sasaki
YSYoshihiko Satoh
Yoshihiko Satoh
YYYukiko Yamamoto
Yukiko Yamamoto
HMHironobu Maezaki
Hironobu Maezaki

12 March 2019 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
RMRyo Mizojiri
Ryo Mizojiri
NNNoriyuki Nii
Noriyuki Nii
MAMoriteru Asano
Moriteru Asano
MSMasako Sasaki
Masako Sasaki
YSYoshihiko Satoh
Yoshihiko Satoh
HMHironobu Maezaki
Hironobu Maezaki

1 April 2021 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Open access
RMRyo Mizojiri
Ryo Mizojiri
DTDaisuke Tomita
Daisuke Tomita
MSMasako Sasaki
Masako Sasaki
YSYoshihiko Satoh
Yoshihiko Satoh
YYYukiko Yamamoto
Yukiko Yamamoto
HMHironobu Maezaki
Hironobu Maezaki
A structure-activity relationship (SAR) study towards novel ACC1-selective inhibitors was carried out by modifying the molecular length of the linker in biaryl derivative 1 g, an ACC1/2 dual inhibitor. Ultimately, this leads us to discover novel phenoxybenzyloxy derivative 1i as a potent ACC1-selective inhibitor. Further chemical modification of this scaffold to improve cellular potency as well as physicochemical and pharmacokinetic (PK) properties produced N-2-(pyridin-2-ylethyl)acetamide derivative 1n, which showed highly potent ACC1-selective inhibition as well as sufficient PK profile for further in vivo evaluations. Oral administration of 1n significantly reduced the concentration of malonyl-CoA in HCT-116 xenograft tumors at doses of 100 mg/kg. Accordingly, our novel series of potent ACC1-selective inhibitors represents a set of useful orally-available research tools, as well as potential therapeutic agents for cancer and fatty acid-related diseases.